(:XLRN)

Nov 17, 2021 02:26 pm ET
Avoro Capital Urges Acceleron Shareholders Not to Tender Into Merck’s Inadequate Offer
Avoro Capital Advisors (“Avoro”), a long-term and collaborative investor in life sciences and biotechnology companies, together with certain of its affiliates and managed funds (“Avoro,” “we” or “us”) beneficially owns approximately 7% of Acceleron Pharma Inc. (Nasdaq: XLRN) (“Acceleron,” “XLRN” or the “Company”), making Avoro one of the Company’s most significant shareholders. Avoro today issued the following statement reiterating why it believes that shareholders should not tender their Acceleron shares into the Merck & Co. Inc. (NYSE: MRK) (“Merck”) tender offer for $180 per share (the “Ten
Nov 09, 2021 05:31 pm ET
Avoro Capital Releases Presentation Detailing Why Acceleron Shareholders Should Not Tender Into Merck’s Inadequate Offer
Avoro Capital Advisors (“Avoro”), a long-term and collaborative investor in life sciences and biotechnology companies, together with certain of its affiliates and managed funds (“Avoro,” “we” or "us") beneficially owns approximately 7% of Acceleron Pharma Inc. (Nasdaq: XLRN) (“Acceleron”, “XLRN” or the “Company”), making Avoro one of the Company's most significant shareholders. Avoro today released a detailed presentation outlining why shareholders should not tender their Acceleron shares to the Merck & Co. Inc. (NYSE: MRK) ("Merck") tender offer for $180 per share (the "Tender Offer").
Nov 04, 2021 06:56 pm ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates ROG, RRD, XLRN, ADMS; Shareholders are Encouraged to Contact the Firm
NEW YORK, Nov. 4, 2021 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:
Nov 04, 2021 04:01 pm ET
Acceleron Reports Third Quarter 2021 Financial Results
Acceleron Pharma Inc. (Nasdaq:XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today reported financial results for the third quarter ended September 30, 2021.
Nov 01, 2021 09:00 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates ZEN, KRA, HFC, INOV, KOR, XLRN; Shareholders are Encouraged to Contact the Firm
NEW YORK, Nov. 1, 2021 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:
Oct 28, 2021 08:00 am ET
Avoro Capital Issues Open Letter to Fellow Acceleron Pharma Shareholders
Avoro Capital Advisors (“Avoro”), a long-term and collaborative investor in life sciences and biotechnology companies, beneficially owns approximately 7% of Acceleron Pharma Inc. (Nasdaq:XLRN) (“Acceleron”, “XLRN” or the “Company”) together with certain of its affiliates and managed funds (“Avoro,” “we” or "us"), making it one of the Company's most significant shareholders. Avoro today issued an open letter to fellow Acceleron shareholders further detailing why the proposed sale of Acceleron to Merck & Co. Inc. (NYSE:MRK) ("Merck") for $180 per share (the "Merger") is not in the best interests
Oct 27, 2021 07:10 am ET
Acceleron Announces Third Quarter 2021 REBLOZYL® Net Sales
Acceleron Pharma Inc. (Nasdaq:XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced net sales of REBLOZYL® (luspatercept-aamt) as reported by its global collaborator, Bristol Myers Squibb, were approximately $160 million for the third quarter ended September 30, 2021. Net sales of REBLOZYL for the third quarter include approximately $20 million to $25 million of sales from an inventory build due to the transition to wholesaler distribution and a
Oct 26, 2021 02:13 pm ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates KRA, ESBK, CXP, KOR, XLRN; Shareholders are Encouraged to Contact the Firm
NEW YORK, Oct. 26, 2021 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:
Oct 20, 2021 12:00 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates UMPQ, KOR, XLRN, VNE; Shareholders are Encouraged to Contact the Firm
Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Umpqua Holdings Corporation (NASDAQ: UMPQ) concerning potential violations of the federal securities laws and/or breaches of fiduciary...
Oct 18, 2021 03:43 pm ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates UMPQ, DSPG, JMP, KOR, XLRN, VNE; Shareholders are Encouraged to Contact the Firm
NEW YORK, Oct. 18, 2021 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:
Oct 18, 2021 11:54 am ET
ACCELERON PHARMA ALERT: Investors Should Contact Bragar Eagel & Squire, P.C. Over Tender Offer for XLRN Shares
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors of Acceleron Pharma Inc. (NASDAQ: XLRN) breached their fiduciary duties or violated the federal securities laws in connection with the company’s acquisition by Merck & Co., Inc. (NYSE: MRK).
Oct 15, 2021 08:21 am ET
(XLRN): Johnson Fistel Investigates Proposed Sale of Acceleron Pharma; Is $180 a Fair Price?
Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Acceleron Pharma Inc. (NASDAQ: XLRN) ("Acceleron" or the "Company") breached their fiduciary duties in connection with the proposed...
Oct 13, 2021 05:56 pm ET
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Acceleron Pharma Inc. - XLRN
NEW YORK, Oct. 13, 2021 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018-2020 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating Acceleron Pharma Inc. (XLRN) relating to its proposed acquisition by Merck & Co., Inc. Under the terms of the agreement, XLRN shareholders are expected to receive $180.00 in cash per share they own.
Oct 13, 2021 03:29 pm ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates XLRN, AZPN, UMPQ, TGP; Shareholders are Encouraged to Contact the Firm
NEW YORK, Oct. 13, 2021 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:
Oct 12, 2021 01:20 pm ET
MERGER ALERT - TGP, XLRN, and VNE: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Mergers of these Companies
NEW YORK, NY / ACCESSWIRE / October 12, 2021 / The following statement is being issued by Levi & Korsinsky, LLP:
Oct 11, 2021 12:54 pm ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates DSPG, XLRN, GSKY, GWB; Shareholders are Encouraged to Contact the Firm
Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: DSP Group, Inc. (NASDAQ: DSPG) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating...
Oct 07, 2021 03:23 pm ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates XLRN, GSKY, GWB, VLY, NOTV; Shareholders are Encouraged to Contact the Firm
NEW YORK, Oct. 7, 2021 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:
Oct 07, 2021 03:15 pm ET
MERGER ALERT - TGP, XLRN, and VNE: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Mergers of these Companies
NEW YORK, NY / ACCESSWIRE / October 7, 2021 / The following statement is being issued by Levi & Korsinsky, LLP:
Oct 06, 2021 03:34 pm ET
Bragar Eagel & Squire, P.C. Announces that it Is Investigating the Boards of Directors of Home BancShares, Valley National, Kraton Corporation, and Acceleron Pharma on behalf of Stockholders and Encou
Bragar Eagel & Squire, P.C. announces to investors that it is investigating potential claims on behalf of stockholders of Home BancShares, Inc. (NASDAQ: HOMB), Valley National Bancorp (NASDAQ: VLY), Kraton Corporation (NYSE: KRA), and Acceleron...
Oct 06, 2021 09:25 am ET
Moore Kuehn Encourages NOTV, ARYD, XLRN, and TGP Investors to Contact Law Firm
Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders.  Moore Kuehn may seek...
Oct 05, 2021 04:55 pm ET
MERGER ALERT - TGP, XLRN, and VNE: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Mergers of these Companies
NEW YORK, NY / ACCESSWIRE / October 5, 2021 / The following statement is being issued by Levi & Korsinsky, LLP:
Oct 04, 2021 02:08 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates XLRN, ADTN, DSPG, KDMN; Shareholders are Encouraged to Contact the Firm
Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Acceleron Pharma Inc. (NASDAQ: XLRN) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties...
Oct 02, 2021 06:03 am ET
Lifshitz Law Firm, P.C. Announces Investigation of XLRN, DVCR, EBMT, and GTS
Acceleron Pharm Inc. (NASDAQGM: XLRN) Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the sale of XLRN to Merck & Co., Inc. for $180.00 in cash per share of XLRN owned. If you are an...
Oct 01, 2021 06:27 pm ET
ACCELERON INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acceleron Pharma Inc. - XLRN
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Acceleron Pharma Inc. (NasdaqGM: XLRN) to Merck (NYSE: MRK). Under the terms of the proposed transaction, shareholders of Acceleron will receive only $180 in cash for each share of Acceleron that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
Oct 01, 2021 02:58 pm ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates XLRN, ADTN, DSPG, KDMN; Shareholders are Encouraged to Contact the Firm
NEW YORK, Oct. 1, 2021 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:
Oct 01, 2021 11:54 am ET
ACCELERON PHARMA ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of XLRN and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors of Acceleron Pharma Inc. (NASDAQ: XLRN) breached their fiduciary duties or violated the federal...
Sep 30, 2021 03:58 pm ET
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of Acceleron Pharma Inc. Buyout
Rigrodsky Law, P.A. announces that it is investigating Acceleron Pharma Inc. (“Acceleron”) (NASDAQ GM: XLRN) regarding possible breaches of fiduciary duties and other violations of law related to Acceleron’s agreement to be acquired by Merck & Co....
Sep 30, 2021 03:52 pm ET
Avoro Capital Believes Proposed Acquisition of Acceleron Pharma by Merck Undervalues Acceleron Pharma
Avoro Capital, a long-term and collaborative investor in life sciences and biotechnology companies, beneficially owns approximately 7% of Acceleron Pharma Inc. (Nasdaq: XLRN) (“Acceleron”, “XLRN” or the “Company”) together with certain of its affiliates and managed funds (“Avoro,” “we” or "us"), making it one of the Company's most significant shareholders. Avoro today issued the following statement:
Sep 30, 2021 01:08 pm ET
Acceleron Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Acceleron Pharma Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – XLRN
Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Acceleron Pharma Inc. (NASDAQ: XLRN) to Merck & Co., Inc. for $180.00 per share in cash is fair to Acceleron shareholders.
Sep 30, 2021 10:17 am ET
Shareholder Alert: Ademi LLP investigates whether Acceleron Pharma Inc. has obtained a Fair Price in its transaction with Merck
MILWAUKEE, Sept. 30, 2021 /PRNewswire/ -- Ademi LLP is investigating Acceleron (Nasdaq: XLRN), for possible breaches of fiduciary duty and other violations of law in its transaction with Merck.
Sep 27, 2021 09:31 am ET
Thinking about trading options or stock in Pfizer, Callon Petroleum, Acceleron Pharma, Tesla, or Expedia Group?
NEW YORK, Sept. 27, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PFE, CPE, XLRN, TSLA, and EXPE.
Aug 05, 2021 04:01 pm ET
Acceleron Reports Second Quarter 2021 Financial Results
Acceleron Pharma Inc. (Nasdaq:XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today reported financial results for the second quarter ended June 30, 2021.
Jul 28, 2021 07:10 am ET
Acceleron Announces Second Quarter 2021 REBLOZYL® Net Sales
Acceleron Pharma Inc. (Nasdaq:XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced net sales of REBLOZYL® (luspatercept-aamt) as reported by its global collaborator, Bristol Myers Squibb, were approximately $128 million for the second quarter ended June 30, 2021.
Jul 26, 2021 07:00 am ET
Acceleron to Webcast Second Quarter 2021 Financial Results on August 5, 2021
Acceleron Pharma Inc. (Nasdaq:XLRN) today announced it will host a webcast and conference call on Thursday, August 5, 2021 at 5:00 p.m. EDT to discuss its second quarter 2021 financial results.
Jun 11, 2021 03:00 am ET
Jun 08, 2021 07:00 am ET
Acceleron to Host Virtual Research and Development (R&D) Day on June 22, 2021
Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced it will host a Virtual R&D Day for analysts and investors on June 22, 2021. The virtual event will take place from 8:00 a.m. to approximately 11:00 a.m. EDT.
May 19, 2021 08:00 am ET
Acceleron Presents Interim Results from the Open-label Extension of the PULSAR Phase 2 Trial of Sotatercept in Patients with Pulmonary Arterial Hypertension (PAH) at the American Thoracic Society 2021
Acceleron Pharma Inc. (NASDAQ:XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today presented at the American Thoracic Society 2021 International Conference (ATS 2021) interim results from the open-label extension of the PULSAR Phase 2 trial of sotatercept in patients with pulmonary arterial hypertension (PAH).
May 19, 2021 08:00 am ET
Acceleron Presents Preliminary Data from the SPECTRA Phase 2 Trial of Sotatercept in Pulmonary Arterial Hypertension (PAH) at the American Thoracic Society 2021 International Conference
Acceleron Pharma Inc. (Nasdaq: XLRN), a leading biopharmaceutical company in the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today presented at the American Thoracic Society 2021 International Conference (ATS 2021) preliminary interim data from the SPECTRA Phase 2 trial of sotatercept in patients with pulmonary arterial hypertension (PAH).
May 12, 2021 10:57 am ET
Acceleron Announces Presentations on REBLOZYL® (luspatercept-aamt) at the 2021 European Hematology Association Virtual Congress
Acceleron Pharma Inc. (Nasdaq: XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced that multiple abstracts on REBLOZYL® (luspatercept-aamt) will be presented at the upcoming 2021 European Hematology Association (EHA2021) Virtual Congress, to be held from June 9-17.
May 11, 2021 07:00 am ET
Acceleron to Host Conference Call and Webcast to Review Clinical Trial Updates, Preclinical Presentations on Sotatercept in Pulmonary Arterial Hypertension (PAH) Presented at the American Thoracic Soc
Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced it will host a conference call and webcast on Wednesday, May 19, 2021 at 10:30 a.m. EDT to review updates from the PULSAR and SPECTRA Phase 2 clinical trials of sotatercept in patients with pulmonary arterial hypertension (PAH). Data from the PULSAR and SPECTRA trials will have been presented during clinical presentations at the American Thoracic Society 2021 International Conferenc
May 06, 2021 04:01 pm ET
Acceleron Reports First Quarter 2021 Financial Results
Acceleron Pharma Inc. (Nasdaq:XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today reported financial results for the first quarter ended March 31, 2021.
Apr 29, 2021 07:10 am ET
Acceleron Announces First Quarter 2021 REBLOZYL® Net Sales
Acceleron Pharma Inc. (Nasdaq:XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced net sales of REBLOZYL® (luspatercept-aamt) as reported by its global collaborator, Bristol Myers Squibb, were approximately $112 million for the first quarter ended March 31, 2021.
Apr 26, 2021 07:00 am ET
Acceleron to Webcast First Quarter 2021 Financial Results on May 6, 2021
Acceleron Pharma Inc. (Nasdaq:XLRN) today announced it will host a webcast and conference call on Thursday, May 6, 2021 at 5:00 p.m. EDT to discuss its first quarter 2021 financial results.
Apr 05, 2021 07:00 am ET
Acceleron Announces Clinical Trial Updates, Preclinical Presentations on Sotatercept in Pulmonary Arterial Hypertension (PAH) at the American Thoracic Society (ATS) 2021 International Conference
Acceleron Pharma Inc. (Nasdaq: XLRN), a leading biopharmaceutical company in the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced that updates from the PULSAR and SPECTRA Phase 2 clinical trials of sotatercept in patients with pulmonary arterial hypertension (PAH) will be presented at the American Thoracic Society 2021 International Conference (ATS 2021), held virtually May 14-19. The Company will also present preclinical research on the effects of a murine version of sotatercept in animal models of PAH and p
Apr 01, 2021 07:00 am ET
New England Journal of Medicine Publishes Results of the PULSAR Phase 2 Trial of Sotatercept in Patients with Pulmonary Arterial Hypertension
Acceleron Pharma Inc. (Nasdaq: XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced that the New England Journal of Medicine has published results of the PULSAR Phase 2 trial of sotatercept in patients with pulmonary arterial hypertension (PAH).
Feb 25, 2021 04:01 pm ET
Acceleron Reports Fourth Quarter and Full Year 2020 Financial Results
Acceleron Pharma Inc. (Nasdaq: XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today reported financial results for the fourth quarter and full year ended December 31, 2020.
Feb 23, 2021 07:00 am ET
Acceleron to Participate in Two Upcoming Healthcare Investor Conferences
Acceleron Pharma Inc. (Nasdaq:XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced that senior management will participate in two upcoming virtual healthcare investor conferences.
Feb 17, 2021 07:00 am ET
Acceleron to Webcast Fourth Quarter and Full Year 2020 Financial Results on February 25, 2021
Acceleron Pharma Inc. (Nasdaq:XLRN) today announced it will host a webcast and conference call on Thursday, February 25, 2021 at 5:00 p.m. EST to discuss its fourth quarter and full year 2020 financial results.
Feb 16, 2021 07:37 am ET
Health Canada Approves REBLOZYL® (luspatercept), New Class of Treatment for Adult Patients Living With Myelodysplastic Syndromes
Bristol Myers Squibb Canada (BMS) and Acceleron Pharma Inc. announced today that Health Canada has approved REBLOZYL® (luspatercept for injection) for the treatment of adult patients with transfusion-dependent anemia requiring at least two RBC red blood cell (RBC) units over 8 weeks resulting from very low-to intermediate-risk myelodysplastic syndromes (MDS) who have ring sideroblasts and who have failed or are not suitable for erythropoietin-based therapy.1 REBLOZYL® represents a new class of treatment for eligible patients as the first and only approved eryth
Feb 04, 2021 07:10 am ET
Acceleron Announces Fourth Quarter and Full Year 2020 REBLOZYL® Net Sales
Acceleron Pharma Inc. (Nasdaq:XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced net sales of REBLOZYL® (luspatercept-aamt) as reported by its global collaborator, Bristol Myers Squibb, were approximately $115 million for the fourth quarter and approximately $274 million for the full year ended December 31, 2020.
Jan 04, 2021 07:00 am ET
Acceleron to Participate in the 39th Annual J.P. Morgan Healthcare Conference on January 11, 2021
Acceleron Pharma Inc. (Nasdaq:XLRN) today announced that Habib Dable, Acceleron’s President and Chief Executive Officer, will present a corporate overview during the 39th Annual J.P. Morgan Healthcare Conference. The presentation will take place on Monday, January 11 at 10:00 a.m. EST, in a virtual format.
Dec 14, 2020 07:00 am ET
Acceleron Receives Orphan Designation from the European Commission (EC) for Sotatercept in Pulmonary Arterial Hypertension (PAH)
Acceleron Pharma Inc. (Nasdaq: XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced that the European Commission (EC) has granted orphan designation to sotatercept for the treatment of patients with pulmonary arterial hypertension (PAH).
Dec 01, 2020 07:00 am ET
Acceleron Receives FDA Orphan Drug Designation for ACE-1334 for the Treatment of Systemic Sclerosis
Acceleron Pharma Inc. (Nasdaq: XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced that the United States Food and Drug Administration (FDA) has granted Orphan Drug designation to ACE-1334 for the treatment of patients with systemic sclerosis. The Company intends to initiate a Phase 1b/Phase 2 trial in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD) in 2021.
Nov 13, 2020 10:01 am ET
Acceleron Presents Preliminary Interim Data from the SPECTRA Phase 2 Trial of Sotatercept in Pulmonary Arterial Hypertension (PAH) at the 2020 American Heart Association Scientific Sessions
Acceleron Pharma Inc. (Nasdaq: XLRN), a leading biopharmaceutical company in the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today presented a set of preliminary interim data from the ongoing SPECTRA Phase 2 trial of sotatercept in patients with pulmonary arterial hypertension (PAH).
Nov 13, 2020 10:00 am ET
Acceleron Presents New Data from the PULSAR Phase 2 Trial, Preclinical Research on Sotatercept in Pulmonary Arterial Hypertension (PAH) at the 2020 American Heart Association (AHA) Scientific Sessions
Acceleron Pharma Inc. (Nasdaq: XLRN), a leading biopharmaceutical company in the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today presented new cardiac and pulmonary function data from the ongoing PULSAR Phase 2 trial of sotatercept in patients with pulmonary arterial hypertension (PAH).
Nov 09, 2020 07:00 am ET
Acceleron Announces Clinical Trial Updates, Preclinical Presentation on Sotatercept in Pulmonary Arterial Hypertension at the 2020 American Heart Association (AHA) Scientific Sessions
Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced that updates from the ongoing PULSAR and SPECTRA Phase 2 clinical trials of sotatercept in patients with pulmonary arterial hypertension (PAH) will be presented at the American Heart Association (AHA) 2020 Scientific Sessions, held virtually November 13-17. The Company will also present preclinical research on the effects of a murine version of sotatercept in an animal model of PAH.
Nov 05, 2020 04:01 pm ET
Acceleron Reports Third Quarter 2020 Operating and Financial Results
Acceleron Pharma Inc. (Nasdaq:XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today provided a corporate update and reported financial results for the third quarter ended September 30, 2020.
Nov 05, 2020 07:15 am ET
Acceleron Announces Third Quarter 2020 REBLOZYL® Net Sales
Acceleron Pharma Inc. (Nasdaq:XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced net sales of REBLOZYL® (luspatercept-aamt) as reported by its global collaborator, Bristol Myers Squibb, were approximately $96 million for the third quarter ended September 30, 2020.
Nov 04, 2020 04:01 pm ET
Acceleron Announces REBLOZYL® (luspatercept-aamt) Virtual Presentations at the 62nd American Society of Hematology Annual Meeting
Acceleron Pharma Inc. (Nasdaq: XLRN), a leading biopharmaceutical company in the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, announced today that data from six clinical abstracts on REBLOZYL (luspatercept-aamt) will be presented at the 62nd American Society of Hematology (ASH) Annual Meeting & Exposition held virtually December 5-8, 2020.
Oct 26, 2020 07:00 am ET
Acceleron to Webcast Third Quarter 2020 Operating and Financial Results on November 5, 2020
Acceleron Pharma Inc. (Nasdaq:XLRN) today announced it will host a webcast and conference call on Thursday, November 5, 2020 at 5:00 p.m. EST to discuss its third quarter 2020 operating and financial results.
Sep 29, 2020 06:59 am ET
Health Canada Approves REBLOZYL® (luspatercept), New Class of Treatment for Adult Patients Living with Beta Thalassemia
Bristol Myers Squibb Canada (BMS) and Acceleron Pharma Inc. (NASDAQ:XLRN) announced today that Health Canada has approved REBLOZYL® (luspatercept) for the treatment of adult patients with red blood cell (RBC) transfusion-dependent anemia associated with beta(β)-thalassemia.1 REBLOZYL® is the first and only erythroid maturation agent in Canada, representing a new class of treatment for eligible patients.1
Sep 17, 2020 04:01 pm ET
Acceleron to Host Webcast Outlining the Design of Its Registrational Phase 3 STELLAR Trial of Sotatercept in Pulmonary Arterial Hypertension (PAH) on October 2, 2020
Acceleron Pharma Inc. (Nasdaq: XLRN), a leading biopharmaceutical company in the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced it will host a conference call and webcast for investors and analysts on Friday, October 2, 2020 at 8:00 a.m. EDT to discuss the design of its first registrational Phase 3 STELLAR trial of sotatercept in patients with pulmonary arterial hypertension (PAH).
Sep 16, 2020 07:00 am ET
Acceleron Appoints Laura J. Hamill to its Board of Directors
Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, announced today the appointment of Laura J. Hamill to its Board of Directors.
Aug 06, 2020 04:01 pm ET
Acceleron Reports Second Quarter 2020 Operating and Financial Results
Acceleron Pharma Inc. (Nasdaq:XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today provided a corporate update and reported financial results for the second quarter ended June 30, 2020.
Aug 06, 2020 07:10 am ET
Acceleron Announces Second Quarter 2020 REBLOZYL® Net Sales
Acceleron Pharma Inc. (Nasdaq:XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced net sales of REBLOZYL® (luspatercept-aamt) in the United States as reported by its global collaborator, Bristol Myers Squibb, were approximately $55.0 million for the second quarter ended June 30, 2020.
Jul 27, 2020 07:00 am ET
Acceleron to Webcast Second Quarter 2020 Operating and Financial Results on August 6, 2020
Acceleron Pharma Inc. (Nasdaq:XLRN) today announced it will host a webcast and conference call on Thursday, August 6, 2020 at 5:00 p.m. EDT to discuss its second quarter 2020 operating and financial results.
Jul 07, 2020 04:04 pm ET
Acceleron Announces Closing of Public Offering of Common Stock and Exercise of Underwriters’ Option to Purchase Additional Shares
Acceleron Pharma Inc. (Nasdaq: XLRN), a leading biopharmaceutical company in the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced that it has issued an aggregate of 5,594,593 shares of common stock at a price of $92.50 per share at the closing of the Company’s previously-announced public offering. The aggregate net proceeds to the Company of the public offering, including pursuant to the full exercise of the underwriters’ option to purchase additional shares and after deducting underwriting discounts and comm
Jul 06, 2020 05:01 pm ET
XLRN Investor Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Acceleron Pharma Inc. and Encourages Investors to Contact the Firm
NEW YORK, July 6, 2020 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Acceleron Pharma Inc. ("Acceleron" or the "Company") (NASDAQ: XLRN). Investors who purchased Acceleron securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/xlrn. 
Jun 30, 2020 06:48 pm ET
Acceleron Announces Pricing of Public Offering of Common Stock
Acceleron Pharma Inc. (Nasdaq: XLRN), a leading biopharmaceutical company in the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced that it has priced an underwritten public offering of 4,864,864 shares of common stock at a price to the public of $92.50 per share for gross proceeds of $450.0 million. In connection with this offering, Acceleron has granted the underwriters a 30-day option to purchase up to an additional 729,729 shares of common stock.
Jun 29, 2020 04:01 pm ET
Acceleron Announces Proposed Public Offering of Common Stock
Acceleron Pharma Inc. (Nasdaq: XLRN), a leading biopharmaceutical company in the discovery, development and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced that it intends to offer and sell, subject to market and other conditions, $400 million of its common stock in an underwritten public offering. As part of this offering, Acceleron intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the public offering. All of the shares in the proposed offer
Jun 26, 2020 09:05 am ET
Jun 24, 2020 03:15 pm ET
Acceleron Presents Topline Results of the PULSAR Phase 2 Trial of Sotatercept in Patients with Pulmonary Arterial Hypertension
Acceleron Pharma Inc. (NASDAQ:XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today presented topline results of the PULSAR Phase 2 trial of sotatercept in patients with pulmonary arterial hypertension (PAH).
Jun 22, 2020 07:00 am ET
Acceleron to Host Conference Call and Webcast to Review Results of PULSAR Phase 2 Trial of Sotatercept Presented at American Thoracic Society 2020 Virtual Conference
Acceleron Pharma Inc. (Nasdaq: XLRN), a leading biopharmaceutical company in the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced it will host a conference call and webcast on Wednesday, June 24, 2020 at 4:30 p.m. EDT to review the topline results of the PULSAR Phase 2 trial of sotatercept in patients with pulmonary arterial hypertension (PAH). Data from the PULSAR trial will have been presented during a virtual session of the American Thoracic Society (ATS) 2020 earlier that day.
Jun 04, 2020 04:05 pm ET
Acceleron Appoints Christopher Hite to its Board of Directors
Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, announced today the appointment of Christopher Hite to its Board of Directors.
May 20, 2020 07:00 am ET
Acceleron Announces Presentations on REBLOZYL® (luspatercept-aamt) at the 2020 American Society of Clinical Oncology and European Hematology Association Virtual Annual Meetings
Acceleron Pharma Inc. (Nasdaq: XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced that a total of six distinct abstracts on REBLOZYL® (luspatercept-aamt) will be presented at the upcoming 2020 American Society of Clinical Oncology 2020 (ASCO20) Virtual Scientific Program, held May 29-31, and at the 25th Annual European Hematology Association (EHA25) Virtual Congress, held June 11-21.
May 19, 2020 07:00 am ET
Acceleron Announces Oral Presentation of PULSAR Phase 2 Trial Results in Virtual American Thoracic Society 2020 Conference Session on June 24, 2020
Acceleron Pharma Inc. (Nasdaq: XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced that an oral presentation of the PULSAR Phase 2 trial topline results of sotatercept in patients with pulmonary arterial hypertension (PAH) will be presented in a virtual session of the American Thoracic Society (ATS) 2020 Conference on June 24, 2020.
May 13, 2020 04:01 pm ET
Acceleron Announces Publication in Science Translational Medicine Describing the Underlying Biology Behind Sotatercept’s Potential as a Novel Therapy in Pulmonary Arterial Hypertension
Acceleron Pharma Inc. (Nasdaq: XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced that research published in the journal Science Translational Medicine describes how a murine version of the investigational agent sotatercept acts to restore balance in key signaling pathways whose disruption drives the disease pathology of pulmonary arterial hypertension (PAH).
May 11, 2020 04:05 pm ET
Acceleron Reports First Quarter 2020 Operating and Financial Results
Acceleron Pharma Inc. (Nasdaq:XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today provided a corporate update and reported financial results for the first quarter ended March 31, 2020.
May 05, 2020 07:00 am ET
Acceleron to Webcast First Quarter 2020 Operating and Financial Results on May 11, 2020
Acceleron Pharma Inc. (Nasdaq:XLRN) today announced it will host a webcast and conference call on Monday, May 11, 2020 at 5:00 p.m. EDT to discuss its first quarter 2020 operating and financial results.
May 04, 2020 07:00 am ET
Acceleron Receives Priority Medicines (PRIME) Designation from European Medicines Agency (EMA) for Sotatercept in Pulmonary Arterial Hypertension
Acceleron Pharma Inc. (Nasdaq: XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced that the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to sotatercept for the treatment of patients with pulmonary arterial hypertension (PAH).
Apr 30, 2020 04:16 pm ET
Reblozyl (luspatercept) Receives Positive CHMP Opinion for the Treatment of Adults with Anemia in Beta Thalassemia and Myelodysplastic Syndromes
Bristol Myers Squibb (NYSE: BMY) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced that the C
Apr 08, 2020 07:05 am ET
Acceleron Receives FDA Breakthrough Therapy Designation for Sotatercept in Pulmonary Arterial Hypertension
Acceleron Pharma Inc. (Nasdaq: XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced that the United States Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to sotatercept for the treatment of patients with pulmonary arterial hypertension (PAH) (World Health Organization Group 1).
Apr 07, 2020 04:05 pm ET
Acceleron Announces Retirement of Director Jean George
Acceleron Pharma Inc. (Nasdaq:XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced that Jean George is retiring from her position on its Board of Directors.
Mar 26, 2020 06:59 am ET
New England Journal of Medicine Publishes Results from Pivotal Phase 3 BELIEVE Trial of Reblozyl (luspatercept-aamt) in Adult Patients With Beta Thalassemia
Bristol-Myers Squibb Company (NYSE:BMY) and Acceleron Pharma Inc. (NASDAQ:XLRN) today announced that the New England Journal of Medicine (NEJM) has published results from BELIEVE, the pivotal Phase 3 study evaluating the safety and efficacy of Reblozyl (luspatercept-aamt) for the treatment of anemia in adults with beta thalassemi
Mar 09, 2020 04:05 pm ET
Acceleron Announces Topline Results from the Phase 2 Trial of ACE-083 in Patients with Charcot-Marie-Tooth Disease
Acceleron Pharma Inc. (NASDAQ:XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced that treatment with ACE-083 in patients with Charcot-Marie-Tooth disease (CMT) did not demonstrate functional improvement in the Phase 2 trial.
Feb 27, 2020 04:05 pm ET
Acceleron Reports Fourth Quarter and Full Year 2019 Operating and Financial Results
Acceleron Pharma Inc. (Nasdaq: XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2019.
Feb 26, 2020 07:00 am ET
Acceleron to Participate in Two Upcoming Healthcare Investor Conferences
Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics intended to treat serious and rare diseases, today announced that senior management will participate in two upcoming healthcare investor conferences.
Feb 18, 2020 07:00 am ET
Acceleron to Webcast Fourth Quarter and Full Year 2019 Operating and Financial Results on February 27, 2020
Acceleron Pharma Inc. (Nasdaq:XLRN) today announced it will host a webcast and conference call on Thursday, February 27, 2020 at 5:00 p.m. EST to discuss its fourth quarter and full year 2019 operating and financial results.
Jan 27, 2020 04:01 pm ET
Acceleron Announces Sotatercept Achieved Primary and Secondary Endpoints in the PULSAR Phase 2 Placebo-Controlled Trial in Patients with Pulmonary Arterial Hypertension
Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced that the PULSAR Phase 2 trial of sotatercept met its primary and key secondary endpoints in patients with pulmonary arterial hypertension (PAH).
Jan 23, 2020 04:15 pm ET
Acceleron Announces Change to Executive Management Team
Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, announced today that John Quisel, J.D., Ph.D, Executive Vice President and Chief Business Officer, is leaving the Company to become Chief Executive Officer of a venture-backed startup biotechnology company. Dr. Quisel’s departure from Acceleron is effective as of February 24.
Jan 09, 2020 06:59 am ET
New England Journal of Medicine Publishes Results of Pivotal Phase 3 Reblozyl® (luspatercept-aamt) MEDALIST Trial
Bristol-Myers Squibb Company (NYSE:BMY) and Acceleron Pharma Inc. (NASDAQ:XLRN) today announced that the New England Journal of Medicine (NEJM) has published results from MEDALIST, the pivotal phase 3 study evaluating the use of Reblozyl® (luspatercept-aamt) to treat anemia in patients with very low- to intermediate-ri
Jan 06, 2020 07:00 am ET
Acceleron to Participate in the 38th Annual J.P. Morgan Healthcare Conference
Acceleron Pharma Inc. (Nasdaq:XLRN) today announced that senior management will participate at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco, California.
Dec 30, 2019 07:30 am ET
Acceleron and Fulcrum Therapeutics Announce Pulmonary Research and Discovery Collaboration Agreement
Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, and Fulcrum Therapeutics, Inc. (Nasdaq:FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced they have entered into a collaboration and license agreement to identify small molecules designed to modulate specific pathways associated with a targeted indication within the pulmonary disease space.
Dec 09, 2019 04:30 pm ET
Reblozyl® (luspatercept-aamt) Studies Evaluating Treatment of Anemia in Rare Blood Diseases Presented at American Society of Hematology (ASH) Annual Meeting
Bristol-Myers Squibb Company (NYSE: BMY) and Acceleron Pharma (NASDAQ: XLRN) today announced data evaluating the erythroid maturation agent (EMA) Reblozyl® (luspatercept-aamt) in patients with anemia associated with a range of serious and rare blood diseases were presented at the 2019 ASH Annual Meeting in Orlando, Fla.
Dec 09, 2019 07:30 am ET
Acceleron Appoints Jay T. Backstrom, M.D., M.P.H., to Newly Created Role as Head of Research and Development
Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, announced today the appointment of Jay T. Backstrom, M.D., M.P.H., as Executive Vice President, Research and Development (R&D). Dr. Backstrom joins Acceleron from Celgene Corporation, where he most recently served as Chief Medical Officer (CMO).
Dec 06, 2019 12:05 pm ET
Bristol-Myers Squibb and Acceleron Pharma Provide Update on FDA Advisory Committee for Reblozyl® (luspatercept-aamt)
Bristol-Myers Squibb Company (NYSE: BMY) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced that following the late-cycle review meeting on December 4, 2019, they were notified by the U.S. Food and Drug Administration (FDA) that Reblozyl (luspatercept-aamt) will not be reviewed at the Oncologic Drugs Advisory Committee (“ODAC”) me
Dec 06, 2019 08:00 am ET
Acceleron Appoints Global Innovation and Drug Development Executive Kemal Malik, MB BS, to its Board of Directors
Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, announced today the appointment of Kemal Malik, MB BS, to its Board of Directors. Dr. Malik, who is currently a member of the Board of Management of Bayer AG, will officially join the Acceleron Board effective January 1, 2020.
Dec 04, 2019 04:01 pm ET
Acceleron Named a “Most Honored” Company in Institutional Investor 2020 “All-America Executive Team” Rankings
Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, announced today that it has been included in the recently released Institutional Investor 2020 “All-America Executive Team” rankings as one of the country’s “Most Honored” companies.
Dec 03, 2019 07:38 am ET
Bristol-Myers Squibb and Acceleron Pharma Announce FDA Advisory Committee Will Review Reblozyl® (luspatercept-aamt) for Use in Patients With Myelodysplastic Syndromes
Bristol-Myers Squibb Company (NYSE: BMY) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced the U.S. Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee will hold a review of Bristol-Myers Squibb’s supplemental Biologics License Application (sBLA) for the use of Reblozyl® (luspatercept-aamt) in patients
Dec 02, 2019 07:00 am ET
Acceleron to Host Conference Call and Webcast to Review Data Presented at the 61st American Society of Hematology Annual Meeting
Acceleron Pharma Inc. (Nasdaq:XLRN) today announced it will host a webcast and conference call on Tuesday, December 10, 2019 at 6:00 a.m. EST to review highlights from its presentations at the 61st American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida, on December 7-10, 2019.
Nov 08, 2019 12:33 pm ET
FDA Approves REBLOZYL® (luspatercept-aamt) for the Treatment of Anemia in Adults With Beta Thalassemia Who Require Regular Red Blood Cell Transfusions
Celgene Corporation (NASDAQ: CELG) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced the U.S. Food and Drug Administration (FDA) has approved REBLOZYL® (luspatercept-aamt) for the treatment of anemia in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions.1 REBLOZYL is not indicated for use as a substitute for RBC transfusions in patients who require immediate correction of anemia.1 REBLOZYL is the first and only FDA-approved erythroid maturation agent, representing a new class of therapy which works by regulating la
Nov 06, 2019 09:05 am ET
Acceleron Announces Luspatercept Presentations at the 61st American Society of Hematology Annual Meeting
Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced that data from six clinical abstracts on luspatercept will be presented at the 61st American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida, on December 7-10, 2019. Luspatercept is being developed as part of a global collaboration between Acceleron and Celgene Corporation.
Nov 06, 2019 07:53 am ET
Acceleron Reports Third Quarter 2019 Operating and Financial Results
Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, today provided a corporate update and reported financial results for the third quarter ended September 30, 2019.
Oct 29, 2019 07:00 am ET
Acceleron to Webcast Third Quarter 2019 Operating and Financial Results on November 6, 2019
Acceleron Pharma Inc. (Nasdaq:XLRN) today announced it will host a webcast and conference call on Wednesday, November 6, 2019 at 10:00 a.m. EST to discuss its third quarter 2019 operating and financial results.
Sep 16, 2019 04:30 pm ET
Acceleron Announces Topline Results from the Phase 2 Trial of ACE-083 in Patients with Facioscapulohumeral Muscular Dystrophy
Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced that treatment with ACE-083 in patients with facioscapulohumeral muscular dystrophy (FSHD) did not achieve functional secondary endpoints in the Phase 2 trial.
Sep 09, 2019 07:00 am ET
Acceleron Receives FDA Orphan Drug Designation for Sotatercept in Pulmonary Arterial Hypertension
Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced that the United States Food and Drug Administration (FDA) has granted Orphan Drug designation to sotatercept for the treatment of patients with pulmonary arterial hypertension (PAH).
Aug 05, 2019 04:05 pm ET
Acceleron Reports Second Quarter 2019 Operating and Financial Results
Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, today provided a corporate update and reported financial results for the second quarter ended June 30, 2019.
Jul 24, 2019 07:00 am ET
Acceleron to Webcast Second Quarter 2019 Operating and Financial Results on August 5, 2019
Acceleron Pharma Inc. (Nasdaq:XLRN) today announced it will host a webcast and conference call on Monday, August 5, 2019 at 5:00 p.m. EDT to discuss its second quarter 2019 operating and financial results.
Jun 26, 2019 07:35 am ET
Acceleron Completes Target Enrollment in the PULSAR Phase 2 Trial of Sotatercept in Pulmonary Arterial Hypertension
Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, announced today it has completed target enrollment of patients with pulmonary arterial hypertension (PAH) in the PULSAR Phase 2 trial of sotatercept. The Company now expects to report top-line results during the first quarter of 2020.
Jun 10, 2019 07:00 am ET
Acceleron Announces Retirement of Director and Co-Founder Tom Maniatis
Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, announced today that company co-founder Tom Maniatis, PhD, is retiring from his position on its Board of Directors and will continue to serve the organization in an advisory capacity as Director Emeritus.
Jun 04, 2019 07:30 am ET
Celgene Corporation and Acceleron Pharma Announce U.S. FDA Accepts Luspatercept Biologics License Application in Myelodysplastic Syndromes and Beta-Thalassemia
Celgene Corporation (NASDAQ: CELG) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced that the U.S. Food and Drug Administration (FDA) has accepted Celgene’s Biologics License Application (BLA) for luspatercept, an investigational erythroid maturation agent, for the treatment of adult patients with very low to intermediate-risk myelodysplastic syndromes (MDS)-associated anemia who have ring sideroblasts and require red blood cell (RBC) transfusions, and for the treatment of adult patients with beta-thalassemia-associated anemia who
May 14, 2019 07:00 am ET
Acceleron to Present at the UBS Global Healthcare Conference
Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced that members of the management team will present at the UBS Global Healthcare Conference on Monday, May 20th, 2019 at 11:00 a.m. EDT in New York, NY.
May 09, 2019 04:05 pm ET
Acceleron Reports First Quarter 2019 Operating and Financial Results
Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, today provided a corporate update and reported financial results for the first quarter ended March 31, 2019.
May 01, 2019 07:00 am ET
Acceleron to Webcast First Quarter 2019 Operating and Financial Results on May 9, 2019
Acceleron Pharma Inc. (Nasdaq:XLRN) today announced it will host a webcast and conference call on Thursday, May 9, 2019 at 5:00 p.m. EDT to discuss its first quarter 2019 operating and financial results.
Apr 26, 2019 07:30 am ET
Celgene Corporation and Acceleron Pharma Announce Submission of Luspatercept Marketing Authorization Application to the European Medicines Agency (EMA) for MDS and Beta-Thalassemia
Celgene Corporation (NASDAQ: CELG) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced that Celgene has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for luspatercept for the treatment of adult patients with very low to intermediate-risk myelodysplastic syndromes (MDS)-associated anemia who have ring sideroblasts, require red blood cell (RBC) transfusions and have received or are not eligible for erythropoiesis-stimulating agents, and for the treatment of adult patients with beta-thalass
Apr 05, 2019 04:01 pm ET
Acceleron Announces Departure of Chief Medical Officer
Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, announced that Robert K. Zeldin, M.D., Chief Medical Officer, is no longer employed by the company, as of today. The company has begun an executive search for his replacement.
Apr 05, 2019 09:28 am ET
Celgene Corporation and Acceleron Pharma Announce Submission of Luspatercept Biologics License Application to U.S. FDA
Celgene Corporation (NASDAQ: CELG) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced that Celgene has submitted a Biologics License Application (BLA) for luspatercept, an erythroid maturation agent, for the treatment of adult patients with very low to intermediate risk myelodysplastic syndromes (MDS)-associated anemia who have ring sideroblasts and require red blood cell (RBC) transfusions and for the treatment of adult patients with beta-thalassemia-associated anemia who require RBC transfusions.
Apr 04, 2019 04:05 pm ET
Acceleron Discontinues Development of Phase 1 Molecule ACE-2494
Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced it is discontinuing development of ACE-2494, a systemic muscle agent the company had been studying in a Phase 1 healthy volunteer trial for the potential treatment of neuromuscular disorders.
Mar 28, 2019 07:10 am ET
Factors of Influence in 2019, Key Indicators and Opportunity within The Ultimate Software Group, New Mountain Finance, Denny's, World Fuel Services, Agree Realty, and Acceleron Pharma — New Research E
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of The Ultimate Software Group, Inc. (NASDAQ:ULTI), New Mountain Finance...
Mar 05, 2019 07:00 am ET
Acceleron Receives FDA Orphan Drug Designation for ACE-083 in Charcot-Marie-Tooth Disease
Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced that the United States Food and Drug Administration (FDA) has granted Orphan Drug designation to ACE-083, the Company’s locally-acting “Myostatin+” muscle agent, for the treatment of patients with Charcot-Marie-Tooth disease (CMT).
Feb 27, 2019 04:05 pm ET
Acceleron Reports Fourth Quarter and Full Year 2018 Operating and Financial Results
Acceleron Pharma Inc. (Nasdaq: XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2018.
Feb 19, 2019 07:00 am ET
Acceleron to Webcast Fourth Quarter and Full Year 2018 Operating and Financial Results on February 27, 2019
Acceleron Pharma Inc. (Nasdaq:XLRN) today announced it will host a webcast and conference call on Wednesday, February 27, 2019 at 5:00 p.m. EST to discuss its fourth quarter and full year 2018 operating and financial results.
Feb 13, 2019 07:00 am ET
Acceleron to Present at Two Upcoming Healthcare Investor Conferences
Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics intended to treat serious and rare diseases, today announced that senior management will present at two upcoming healthcare investor conferences.
Jan 22, 2019 07:30 am ET
Consolidated Research: 2019 Summary Expectations for Marathon Petroleum, AMC Entertainment, JetBlue Airways, Acceleron Pharma, Natera, and AquaVenture — Fundamental Analysis, Key Performance Indicatio
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Marathon Petroleum Corporation (NYSE:MPC), AMC Entertainment Holdings,...
Jan 16, 2019 07:00 am ET
Acceleron Announces Pricing of Public Offering of Common Stock
Acceleron Pharma Inc. (Nasdaq: XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics intended to treat serious and rare hematologic, neuromuscular, and pulmonary diseases, today announced that it has priced an underwritten public offering of 5,348,838 shares of common stock at a price to the public of $43.00 per share for gross proceeds of $230.0 million. In connection with this offering, Acceleron has granted the underwriters a 30-day option to purchase up to an additional 802,325
Jan 14, 2019 04:04 pm ET
Acceleron Announces Proposed Public Offering of Common Stock
Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare hematologic, neuromuscular, and pulmonary diseases, today announced that it intends to offer and sell, subject to market and other conditions, $200 million of its common stock in an underwritten public offering. As part of this offering, Acceleron intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock
Jan 10, 2019 07:00 am ET
Acceleron Announces Publication of Luspatercept Phase 2 Beta-Thalassemia Study Results in Blood
Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced that the journal Blood has published results from the Phase 2 study of luspatercept in patients with red blood cell (RBC) transfusion-dependent and non-transfusion-dependent beta-thalassemia. Luspatercept is an investigational therapy that is part of a global collaboration between Acceleron and Celgene.
Jan 02, 2019 07:00 am ET
Acceleron to Webcast Presentation at the 37th Annual J.P. Morgan Healthcare Conference
Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced that Habib Dable, President and Chief Executive Officer, will present an overview of the company along with its upcoming corporate priorities at the 37th Annual J.P. Morgan Healthcare Conference on Monday, January 7, 2019 at 2:00 p.m. PST / 5:00 p.m. EST in San Francisco, California.
Dec 05, 2018 04:30 pm ET
Acceleron Announces Luspatercept Phase 3 MEDALIST and BELIEVE Presentations Selected for “Best of ASH” by the American Society of Hematology
Acceleron Pharma Inc. (Nasdaq:XLRN) today announced that the presentations of the MEDALIST and BELIEVE Phase 3 trial results of luspatercept in patients with lower-risk myelodysplastic syndromes (MDS) and beta-thalassemia associated anemias, respectively, were selected for “Best of ASH” by the American Society of Hematology at its 60th Annual Meeting & Exposition in San Diego. Luspatercept is an investigational therapy that is part of a global collaboration between Acceleron and Celgene.
Dec 03, 2018 07:30 am ET
Detailed Research: Economic Perspectives on Honeywell International, Tabula Rasa Healthcare, El Pollo Loco, Acceleron Pharma, vTv Therapeutics, and 22nd Century Group — What Drives Growth in Today's C
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Honeywell International Inc. (NYSE:HON), Tabula Rasa Healthcare Inc....
Dec 01, 2018 05:00 pm ET
Celgene Corporation and Acceleron Pharma Announce Results of the Phase 3 BELIEVE Trial Evaluating Luspatercept in Adult Patients with Beta-Thalassemia at ASH 2018
Celgene Corporation (NASDAQ: CELG) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced results from a pivotal, phase 3 trial (BELIEVE) evaluating the safety and efficacy of luspatercept for the treatment of adults with beta-thalassemia-associated anemia who require regular red blood cell (RBC) transfusions. The data were presented by Maria Domenica Cappellini, M.D. in an oral session of the 60th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, CA (Abstract #163).
Nov 28, 2018 07:00 am ET
Acceleron Receives FDA Fast Track Designation for ACE-083 in Charcot-Marie-Tooth Disease
Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced that the United States Food and Drug Administration (FDA) has granted Fast Track designation to ACE-083, the Company’s locally-acting “Myostatin+” muscle agent, for the treatment of patients with Charcot-Marie-Tooth disease (CMT).
Nov 27, 2018 07:00 am ET
Acceleron to Host Conference Call and Webcast to Review MEDALIST and BELIEVE Phase 3 Trial Presentations of Luspatercept at the 60th American Society of Hematology Annual Meeting
Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced it will host a conference call and live audio webcast on Monday, December 3, 2018 at 9:00 a.m. EST to review the MEDALIST and BELIEVE Phase 3 trial presentations of luspatercept at the 60th American Society of Hematology (ASH) Annual Meeting and Exposition taking place on December 1-4, 2018 in San Diego, California.
Nov 26, 2018 07:00 am ET
Acceleron to Participate in Two Upcoming Healthcare Investor Conferences
Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced that senior management will participate in two upcoming healthcare investor conferences.
Nov 07, 2018 07:00 am ET
Acceleron Announces Preclinical Presentations on Sotatercept in Pulmonary Arterial Hypertension at the 2018 American Heart Association Scientific Session
Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced plans to deliver three preclinical presentations on sotatercept in Pulmonary Arterial Hypertension (PAH) at the 2018 American Heart Association (AHA) Scientific Session in Chicago, IL, November 10-12, 2018.
Nov 01, 2018 09:01 am ET
Acceleron Announces that Phase 3 Results from the MEDALIST and BELIEVE Trials of Luspatercept will be Presented at the 60th American Society of Hematology Annual Meeting
Acceleron Pharma Inc. (Nasdaq:XLRN) today announced that results from the MEDALIST and BELIEVE Phase 3 trials of luspatercept in patients with low-to-intermediate risk myelodysplastic syndromes (MDS) and transfusion-dependent beta-thalassemia, respectively, will be presented at the 60th American Society of Hematology (ASH) Annual Meeting & Exposition in San Diego, California, on December 1-4, 2018. Luspatercept is being developed as part of a global collaboration between Acceleron and Celgene.
Oct 30, 2018 04:05 pm ET
Acceleron Reports Third Quarter 2018 Operating and Financial Results
Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today provided a corporate update and reported financial results for the third quarter ended September 30, 2018.
Oct 24, 2018 07:20 am ET
Research Report Identifies Cato, Roadrunner Transportation, Talend S.A, Vi, MannKind, and Acceleron Pharma with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Cato Corporation (NYSE:CATO), Roadrunner Transportation Systems, Inc...
Oct 23, 2018 07:00 am ET
Acceleron to Webcast Third Quarter 2018 Operating and Financial Results on October 30, 2018
Acceleron Pharma Inc. (Nasdaq:XLRN) today announced it will host a webcast and conference call on Tuesday, October 30, 2018 at 4:30 p.m. EDT to discuss its third quarter 2018 operating and financial results.
Oct 16, 2018 07:00 am ET
Acceleron to Host Pulmonary Arterial Hypertension Research and Development Deep Dive Event on November 16, 2018 in New York City
Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced it will webcast a live presentation from its Pulmonary Arterial Hypertension (PAH) Research and Development Deep Dive event on Friday, November 16, 2018. The event will take place from 9:00 a.m. to 12:00 p.m. EST in New York City.
Sep 27, 2018 07:00 am ET
Acceleron Announces Presentations on ACE-083 at the 23rd International Annual Congress of the World Muscle Society
Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced plans to deliver poster presentations on ACE-083 from Part 1 of each its ongoing Phase 2 trials in patients with facioscapulohumeral muscular dystrophy (FSHD) and Charcot-Marie-Tooth disease (CMT) at the 23rd International Annual Congress of the World Muscle Society to be held in Mendoza, Argentina, October 2-6, 2018.
Sep 04, 2018 07:00 am ET
Acceleron to Participate in Three Upcoming Healthcare Investor Conferences
Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced that senior management will participate in three upcoming healthcare investor conferences.
Aug 02, 2018 04:05 pm ET
Acceleron Reports Second Quarter 2018 Operating and Financial Results
Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today provided a corporate update and reported financial results for the second quarter ended June 30, 2018.
Jul 26, 2018 07:00 am ET
Acceleron to Webcast Second Quarter 2018 Operating and Financial Results on August 2, 2018
Acceleron Pharma Inc. (NASDAQ:XLRN) today announced it will host a webcast and conference call on Thursday, August 2, 2018 at 5:00 p.m. EDT to discuss its second quarter 2018 operating and financial results.
Jul 23, 2018 07:00 am ET
Acceleron Announces Preliminary Results from Part 1 of the ACE-083 Phase 2 Trial in Patients with Charcot-Marie-Tooth Disease at the 2018 Annual Meeting of the Peripheral Nerve Society
Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced positive preliminary results from Part 1 of the Phase 2 clinical trial with ACE-083 in patients with Charcot-Marie-Tooth (CMT) disease at the Peripheral Nerve Society (PNS) annual meeting held in Baltimore, Maryland. CMT is one of the most common inherited neurological diseases and is associated with significant focal muscle weakness. The Company plans to initiate P
Jul 12, 2018 07:00 am ET
Acceleron Receives FDA Orphan Drug Designation for ACE-083 in Facioscapulohumeral Muscular Dystrophy
Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced that the United States Food and Drug Administration (FDA) has granted orphan drug designation for ACE-083, the Company’s locally acting “Myostatin+” muscle agent, for the treatment of patients with facioscapulohumeral muscular dystrophy (FSHD).
Jul 09, 2018 04:52 pm ET
Celgene and Acceleron Announce Luspatercept Achieved Primary and All Key Secondary Endpoints in Phase III ‘BELIEVE’ Study in Adults with Transfusion-Dependent Beta-Thalassemia
Celgene Corporation (NASDAQ: CELG) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced results from a phase III, randomized, double-blind, multi-center clinical study (BELIEVE). Luspatercept achieved a highly statistically significant improvement in the primary endpoint of erythroid response, which was defined as at least a 33 percent reduction from baseline in red blood cell (RBC) transfusion burden with a reduction of at least 2 units during the protocol-defined period of 12 consecutive weeks, from week 13 to week 24, compared to p
Jul 05, 2018 04:30 pm ET
Acceleron Appoints Robert K. Zeldin, M.D., Chief Medical Officer
Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced the appointment of Robert K. Zeldin, M.D., as Chief Medical Officer (CMO). Dr. Zeldin brings to Acceleron more than two decades of clinical, regulatory and industry experience, most recently serving as CMO of Belgium-based Ablynx NV.
Jun 28, 2018 04:30 pm ET
Celgene and Acceleron Announce Luspatercept Achieved Primary and Key Secondary Endpoints in Phase III ‘MEDALIST’ Study in Patients with Low-to-Intermediate Risk Myelodysplastic Syndromes
Celgene Corporation (NASDAQ: CELG) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced results from a phase III, randomized, double-blind, multi-center clinical study (MEDALIST). Luspatercept achieved a highly statistically significant improvement in the primary endpoint of red blood cell (RBC) transfusion independence of at least 8 consecutive weeks during the first 24 weeks compared to placebo.
Jun 26, 2018 07:00 am ET
Acceleron to Present Preliminary Data on ACE-083 at the 2018 Annual Meeting of the Peripheral Nerve Society
Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced plans to deliver oral and poster presentations on ACE-083 from the ongoing Phase 2 trial in patients with Charcot-Marie-Tooth (CMT) disease at the Peripheral Nerve Society (PNS) annual meeting held in Baltimore, Maryland, July 22-25, 2018.
Jun 22, 2018 07:30 am ET
Market Trends Toward New Normal in RCI Hospitality, Phillips 66 Partners LP, Acceleron Pharma, Destination Maternity, The RMR Group, and Cohen & Steers — Emerging Consolidated Expectations, Analyst Ra
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of RCI Hospitality Holdings, Inc. (NASDAQ:RICK), Phillips 66 Partners LP...
Jun 15, 2018 07:00 am ET
Acceleron Announces Updated Results from Ongoing Phase 2 Trials of Luspatercept in Beta-Thalassemia at the 23rd Congress of the European Hematology Association
Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced updated results from the ongoing Phase 2 trials of luspatercept in patients with beta-thalassemia during an oral presentation at the 23rd Congress of the European Hematology Association (EHA) in Stockholm, Sweden. Luspatercept is being developed as part of a global collaboration between Acceleron and Celgene.
Jun 04, 2018 07:00 am ET
Acceleron Announces Updated Results from Ongoing Phase 2 Trials of Luspatercept in Myelodysplastic Syndromes at the ASCO 2018 Annual Meeting
Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced updated results from the Phase 2 trials of luspatercept in patients with lower-risk myelodysplastic syndromes (MDS) at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting in Chicago. Luspatercept is being developed as part of a global collaboration between Acceleron and Celgene.
May 22, 2018 07:00 am ET
Acceleron Announces Initiation of PULSAR Phase 2 Trial of Sotatercept in Pulmonary Arterial Hypertension
Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced the initiation of the PULSAR Phase 2 trial of sotatercept for the treatment of patients with pulmonary arterial hypertension (PAH), a chronic and life-changing disease that can lead to heart failure.
May 17, 2018 09:21 am ET
Acceleron Announces Presentations on Luspatercept at the 23rd Congress of the European Hematology Association
Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced plans to deliver three presentations on luspatercept at the 23rd Congress of the European Hematology Association (EHA) in Stockholm, Sweden on June 14-17, 2018. Luspatercept is being developed as part of a global collaboration between Acceleron and Celgene.
May 08, 2018 04:01 pm ET
Acceleron Reports First Quarter 2018 Operating and Financial Results
Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today provided a corporate update and reported financial results for the first quarter ended March 31, 2018.
May 03, 2018 07:55 am ET
Factors of Influence in 2018, Key Indicators and Opportunity within Sonic Automotive, STERIS plc, AquaVenture, Senseonics, Acceleron Pharma, and Steelcase — New Research Emphasizes Economic Growth
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Sonic Automotive, Inc. (NYSE:SAH), STERIS plc (NYSE:STE), AquaVenture...
May 02, 2018 07:00 am ET
Acceleron to Participate in Two Healthcare Investor Conferences in May
Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced that senior management will participate in two upcoming healthcare investor conferences in May.
May 01, 2018 07:00 am ET
Acceleron Receives FDA Fast Track Designation for ACE-083 in Facioscapulohumeral Muscular Dystrophy (FSHD)
Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ACE-083, a locally-acting “Myostatin+” muscle agent, for the treatment of patients with facioscapulohumeral muscular dystrophy (FSHD).
Apr 30, 2018 07:00 am ET
Acceleron to Webcast First Quarter 2018 Operating and Financial Results on May 8, 2018
Acceleron Pharma Inc. (NASDAQ:XLRN) today announced it will host a webcast and conference call on Tuesday, May 8, 2018 at 5:00 p.m. EDT to discuss its first quarter 2018 operating and financial results.
Apr 26, 2018 08:00 am ET
Acceleron Announces ACE-083 Phase 2 Trial Presentation at the American Academy of Neurology 70th Annual Meeting
Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced that preliminary results from the ongoing Phase 2 trial of ACE-083 in facioscapulohumeral muscular dystrophy (FSHD) are being presented at the American Academy of Neurology (AAN) 70th Annual Meeting in Los Angeles, California on April 26, 2018.
Apr 26, 2018 07:00 am ET
Acceleron Announces Presentations on Lead Product Candidate Luspatercept at the 2018 American Society of Clinical Oncology Annual Meeting
Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced that two abstracts on lead product candidate luspatercept will be presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, Illinois on June 1-5, 2018. Luspatercept is being developed as part of a global collaboration between Acceleron and Celgene.
Mar 20, 2018 08:30 am ET
Report: Developing Opportunities within Heico, Global Medical REIT, Acceleron Pharma, Momenta Pharmaceuticals, Silgan, and Weingarten Realty Investors — Future Expectations, Projections Moving into 20
NEW YORK, March 20, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Heico Corporation (NYSE:HEI-A), Global Medical REIT...
Mar 12, 2018 07:00 am ET
Acceleron to Host Educational Webinar with Leading Clinicians to Provide an Overview of Pulmonary Arterial Hypertension (PAH) and the Sotatercept Phase 2 Trial
Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced that it will host an educational webinar on pulmonary arterial hypertension (PAH) and the Company’s Phase 2 clinical trial of sotatercept in patients with PAH. The webinar will be led by Acceleron’s senior management team and PAH disease experts, Aaron B. Waxman, M.D., Ph.D., and David Badesch, M.D. The webinar is scheduled for Wednesday, March 28, 2018 at 8:00 a.m.
Feb 28, 2018 07:04 am ET
Acceleron Announces Publication of ACE-083 Phase 1 Trial Results in Muscle & Nerve
Acceleron Pharma Inc. (NASDAQ: XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced that the journal Muscle & Nerve has published the final results from the Phase 1 trial of ACE-083, the Company's locally acting, “Myostatin+”, muscle agent. ACE-083 treatment generated dose-dependent mean total muscle volume increases of up to 14.5% in the rectus femoris (RF) and 8.9% in the tibialis anterior (TA) three weeks after the last dose.
Feb 27, 2018 04:05 pm ET
Acceleron Reports Fourth Quarter and Full Year 2017 Operating and Financial Results
Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2017.
Feb 27, 2018 01:00 pm ET
Acceleron Pharma Inc to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / February 27, 2018 / Acceleron Pharma Inc (NASDAQ: XLRN) will be discussing their earnings results in their Q4 Earnings Call to be held on February 27, 2018 at 5:00 PM Eastern Time.
Feb 20, 2018 07:00 am ET
Acceleron to Webcast Fourth Quarter and Full Year 2017 Operating and Financial Results on February 27, 2018
Acceleron Pharma Inc. (NASDAQ:XLRN) today announced it will host a webcast and conference call on Tuesday, February 27, 2018 at 5:00 p.m. EST to discuss its fourth quarter and full year 2017 operating and financial results.
Feb 08, 2018 04:01 pm ET
Acceleron Announces Appointment of Chief Commercial Officer
Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced the appointment of commercial industry leader, Sujay Kango as Chief Commercial Officer (CCO). He brings over 25 years of commercial leadership and expertise, in both biotechnology and large pharmaceutical companies. Throughout his career, Mr. Kango has led multiple global product launches, including Kyprolis® and Remicade ®, built commercial te
Jan 31, 2018 07:00 am ET
Acceleron to Present at the Leerink Partners 7th Annual Global Healthcare Conference
Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced that members of the management team will present at the Leerink Partners 7th Annual Global Healthcare Conference on February 15, 2018 at 3:30 p.m. EST in New York, NY.
Jan 17, 2018 08:20 am ET
Consolidated Research: 2018 Summary Expectations for Eclipse Resources, Unit, Post, Acceleron Pharma, SELECT EGY SVCS, and Concho Resources — Fundamental Analysis, Key Performance Indications
NEW YORK, Jan. 17, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Eclipse Resources Corporation (NYSE:ECR), Unit Corporation...
Jan 08, 2018 11:05 am ET
Acceleron Announces Preliminary Results from Part 1 of the ACE-083 Phase 2 Trial in Patients with Facioscapulohumeral Dystrophy
Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced positive preliminary results for the first two cohorts in Part 1 of the Phase 2 clinical trial with ACE-083 in patients with facioscapulohumeral dystrophy (FSHD), a rare genetic muscle disorder that results in progressive focal muscle loss and weakness. The Company plans to initiate Part 2 of the ACE-083 FSHD Phase 2 trial during the second quarter of 2018.
Jan 03, 2018 07:00 am ET
Acceleron Announces Planned Retirement of Chief Medical Officer, Dr. Matthew L. Sherman
Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced the planned retirement of Executive Vice President and Chief Medical Officer Matthew L. Sherman, M.D. The retirement will be effective after the topline data release from the ongoing MEDALIST and BELIEVE Phase 3 clinical trials with luspatercept, expected to occur in the middle of this year. Luspatercept is the Company’s lead program that is being developed across m
Jan 02, 2018 07:00 am ET
Acceleron to Webcast Presentation at the 36th Annual J.P. Morgan Healthcare Conference
Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced that Habib Dable, President and Chief Executive Officer, will present at the 36th Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2018 at 2:30 p.m. PST / 5:30 p.m. EST at the Westin St. Francis Hotel in San Francisco, California.
Dec 10, 2017 09:00 am ET
Acceleron Announces Updated Results from Ongoing Phase 2 Trials of Luspatercept in Myelodysplastic Syndromes at the 59th Annual Meeting of the American Society of Hematology
Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced preliminary results from the ongoing Phase 2 trials with luspatercept in patients with lower-risk myelodysplastic syndromes (MDS) at the 59th Annual Meeting of the American Society of Hematology (ASH) in Atlanta, Georgia. Luspatercept is being developed as part of a global collaboration between Acceleron and Celgene.
Dec 05, 2017 07:00 am ET
Acceleron to Host Conference Call and Webcast to Review Data Presented at the 59th American Society of Hematology Annual Meeting and Exposition
Acceleron Pharma Inc. (NASDAQ:XLRN) will host a conference call and live audio webcast on Monday, December 11, 2017 at 7:00 a.m. EST to review highlights from its Phase 2 clinical presentations at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition taking place December 9-12, 2017 in Atlanta, Georgia.
Nov 15, 2017 04:01 pm ET
Acceleron Announces Appointment of Dr. Karen Smith to its Board of Directors and Departure of Terrance McGuire
Acceleron Pharma Inc. (NASDAQ:XLRN) today announced the appointment of the experienced biopharmaceutical executive, Karen Smith, M.D., Ph.D., to its board of directors and the departure of Terrance McGuire, effective November 15, 2017.
Nov 14, 2017 04:01 pm ET
Acceleron Announces Preclinical Results in Pulmonary Arterial Hypertension at the American Heart Association 2017 Scientific Sessions
Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced new preclinical results with sotatercept in pulmonary arterial hypertension (PAH) during an oral presentation at the American Heart Association (AHA) 2017 Scientific Sessions in Anaheim, California.
Nov 07, 2017 07:00 am ET
Acceleron Pharma Reports Third Quarter 2017 Operational and Financial Results
Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today provided a corporate update and reported financial results for the third quarter ended September 30, 2017.
Nov 01, 2017 09:19 am ET
Acceleron to Present Clinical Presentations at the 59th American Society of Hematology Annual Meeting and Exposition
Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced that two abstracts have been accepted for presentation at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition in Atlanta, Georgia on December 9-12, 2017.
Oct 26, 2017 07:00 am ET
Acceleron to Webcast Third Quarter 2017 Financial Results on November 7, 2017
Acceleron Pharma Inc. (NASDAQ:XLRN) today announced it will host a webcast and conference call on Tuesday, November 7, 2017 at 8:00 a.m. EST to discuss its third quarter 2017 financial results and provide an update on recent clinical development and corporate activities.
Oct 05, 2017 07:00 am ET
Acceleron Announces Closing of Underwriters’ Option to Purchase Additional Shares
Acceleron Pharma Inc. (NASDAQ: XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced that it has issued 810,810 shares of common stock at the public offering price of $37.00 per share, pursuant to the full exercise of the underwriters’ over-allotment option in connection with the Company’s previously announced public offering of common stock. The aggregate net proceeds to the Company of the public offering, including the full exercise of the
May 01, 2017 10:13 am ET
Leading Protein Scientist Dr. Asya Grinberg Joins Dragonfly Therapeutics as Head of Biologics
CAMBRIDGE, Mass., May 1, 2017 /CNW/ -- Dragonfly Therapeutics, Inc. ("Dragonfly"), today announced the addition of Dr. Asya Grinberg to its senior team. Dr. Grinberg joins Dragonfly from Acceleron Pharma (Nasdaq: XLRN), where she led a multidisciplinary team in cell biology and protein chemistry. As Dragonfly's Head of Biologics, Dr. Grinberg leads its protein engineering, purification, characterization and structural biology team.
May 01, 2017 10:13 am ET
Leading Protein Scientist Dr. Asya Grinberg Joins Dragonfly Therapeutics as Head of Biologics
CAMBRIDGE, Mass., May 1, 2017 /PRNewswire/ -- Dragonfly Therapeutics, Inc. ("Dragonfly"), today announced the addition of Dr. Asya Grinberg to its senior team. Dr. Grinberg joins Dragonfly from Acceleron Pharma (Nasdaq: XLRN), where she led a multidisciplinary team in cell biology and protein chemistry. As Dragonfly's Head of Biologics, Dr. Grinberg leads its protein engineering, purification, characterization and structural biology team.

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.